In addition, accumulating evidence from recent randomized clinical trials employing AHSCT suggest that the combination of a better cardiac evaluation of SSc patients, in association with CD-34+ selection in the mobilization phase and a reduced dose of CYC in the conditioning phase, confers a favorable long-term overall survival with an acceptable safety profile [14]. The gene discussed is CD34; the disease is systemic sclerosis.